says its second radiopharmaceutical candidate, DEP HER2-lutetium, achieved potent and durable anticancer activity, with complete tumour regression, outperforming Herceptin labelled with lutetium, in a breast cancer model.
Worldwide, breast cancer is the most common cancer in women and the second most common cancer in the US.
Radiotheranostics is a rapidly developing area of cancer treatment and diagnosis, with deals and sales estimated to grow to $12–15 billion by 2030.
Recent deals include the acquisition of Endocyte by Novartis for US$2.1 billion and the acquisition of Sirtex by CDH Genetech for $1.9 billion.
Shares in Starpharma (ASX:SPL)
are trading 1.1 per cent higher at $1.89.